RECRUITINGINTERVENTIONAL

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

About This Trial

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosed with epilepsy - Currently prescribed anti-seizure medicine (ASMs) - Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) - Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study - Are between 18-24 years old and able to provide willing to sign a consent form - Able to read, speak, and write in English - Resides in Florida - Receive outpatient medical services Who Should NOT Join This Trial: - They do not own a mobile device with internet access. - They have a history of severe intellectual disability. - They are unable to operate a mobile device (keyboard or touchscreen). - Reside in an in-patient setting. - Adults unable to consent. - Pregnant women (excluded because pregnancy is not relevant to the study focus). - Prisoners. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Diagnosed with epilepsy * Currently prescribed anti-seizure medicine (ASMs) * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) * Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study * Are between 18-24 years old and able to provide informed consent * Able to read, speak, and write in English * Resides in Florida * Receive outpatient medical services Exclusion Criteria: * They do not own a mobile device with internet access. * They have a history of severe intellectual disability. * They are unable to operate a mobile device (keyboard or touchscreen). * Reside in an in-patient setting. * Adults unable to consent. * Pregnant women (excluded because pregnancy is not relevant to the study focus). * Prisoners.

Treatments Being Tested

OTHER

Medilepsy® Chatbot AI-Enhanced

Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.

OTHER

Medilepsy® Chatbot Standard

Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.

Locations (1)

University of Central Florida

Orlando, Florida, United States